Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10087259 Depleting tumor-specific tregs

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Alexander Rudensky0

George Plitas0

Date of Patent

October 2, 2018

0

Patent Application Number

146986000

Date Filed

April 28, 2015

0

Patent Citations Received

US Patent 12065497 Methods of treatment using CCR8 antibodies

0

US Patent 11639393 Anti-CCR8 antibodies

0

US Patent 11692038 Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)

0

US Patent 11427640 CCR8 antibodies for therapeutic applications

US Patent 11873342 Anti-CCR8 monoclonal antibodies and uses thereof

0

US Patent 11932696 Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells

0

US Patent 10550191 Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8

0

Patent Primary Examiner

Daniel C Gamett

0

Patent abstract

The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10087259 Depleting tumor-specific tregs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool